Novavax receives interim authorisation in Singapore for Covid-19 vaccine

Novavax has received interim authorisation from the Singapore Health Sciences Authority (HSA) for its recombinant, adjuvanted Covid-19 vaccine, Nuvaxovid (NVX-CoV2373). The vaccine is intended for active immunisation to prevent the disease in people aged 18 years and above. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 viral strain. The vaccine is formulated with the company’s Matrix-M, a saponin-based adjuvant to boost immune response and elicit greater neutralising antibody levels.